ArticleJBRA assisted reproduction2026
L-arginine attenuates cisplatin-induced sexual dysfunction in male Wistar rats by modulating circulating testosterone and NO/cGMP signaling.
Article in JBRA assisted reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCisplatin is a highly potent and commonly used antineoplastic agent. However, it has been reported to induce male sexual dysfunction (SD) via the downregulation of testosterone and nitric oxide (NO)/ cyclic guanosine monophosphate (cGMP) signaling. On the other hand, L-arginine upregulates NO/cGMP signaling and may attenuate cisplatin-induced male sexual dysfunction. Thus, the current study examined the effect of L-arginine on cisplatin-induced male SD with a focus on testosterone bioavailability and NO/cGMP as a potential target pathway.
methodsTwenty-four male Wistar rats were allotted randomly to four groups: control, L-arginine-treated, cisplatin-treated, and cisplatin co-treatment with L-arginine.
resultsCisplatin therapy significantly lowered libido and sexual vigor, evinced by extended mount, intromission, and ejaculation latencies and reduced motivation to mate and mount, intromission, and ejaculation frequencies, as well as penile reflex. Moreover, cisplatin downregulated circulating testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH). In addition, cisplatin exposure markedly reduced dopamine and cavernosal levels of NO and cGMP and increased cavernosal acetylcholinesterase, monoamine oxidase, and arginase. Also, cisplatin increased cavernosal malondialdehyde, NF-kB, TNF-α, IL-1β, and IL-6 but reduced GSH, SOD, and catalase. However, co-administration of L-arginine attenuated cisplatin-induced SD by improving the indices of the male sex act and upregulating testosterone, LH, FSH, NO, cGMP, and dopamine. Arginine co-therapy also suppressed cytokine levels and improved penile redox state.
conclusionsL-arginine attenuates cisplatin-induced male SD by modulating circulating testosterone and NO/cGMP signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.